A Phase 3 interventional study of Moxidectin and Ivermectin in Onchocerciasis, sponsored by Medicines Development for Global Health. Completed at 2 sites in 2 countries. Open to participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Medicines Development for Global Health · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.
35 studies on the registry are indexed under Onchocerciasis; 7 are open to participants now.
This study's enrollment of 12,979 is above the median of 216 across 26 interventional studies indexed under Onchocerciasis.
Browse Onchocerciasis studies →Medicines Development for Global Health is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In onchocerciasis endemic areas: Moxidectin 8 mg per oral on Day 0
Drug: Moxidectin
In onchocerciasis endemic areas: Ivermectin treatment with approximately 150 µg/kg per oral determined based on height on Day 0
Drug: Ivermectin
In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Moxidectin 8 mg per oral with concomitant albendazole 400 mg per oral on Day 0
Drug: Moxidectin · Drug: Albendazole
In onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity: Ivermectin treatment with approximately 150 microgram/kilogram (μg/kg) per oral determined based on height with concomitant albendazole 400 mg per oral on Day 0
Drug: Ivermectin · Drug: Albendazole
2 mg tablets, encapsulated for blinding
3 mg tablets, encapsulated for blinding
400 mg tablets
Incidence and Severity of Treatment Emergent Adverse Events
Participant incidence rates of treatment emergent adverse events following a single dose of moxidectin versus a single dose of ivermectin will be assessed separately by endemic area. Treatment emergent adverse events may also be pooled across both endemic areas (pooled monotherapy and combination therapies separately for moxidectin and ivermectin), provided a qualitative assessment shows they are similar enough to enable the interpretation of the pooled analysis.
Time frame: Up to 3 months
| Milestone | Moxidectin | Ivermectin | Moxidectin Plus Albendazole | Ivermectin Plus Albendazole |
|---|---|---|---|---|
| Started | 6421 | 1605 | 3959 | 994 |
| Completed | 6395 | 1592 | 3891 | 977 |
| Not completed | 26 | 13 | 68 | 17 |
Participant incidence rates of treatment emergent adverse events following a single dose of moxidectin versus a single dose of ivermectin will be assessed separately by endemic area. Treatment emergent adverse events may also be pooled across both endemic areas (pooled monotherapy and combination therapies separately for moxidectin and ivermectin), provided a qualitative assessment shows they are similar enough to enable the interpretation of the pooled analysis.
| participants | Moxidectin | Ivermectin | Moxidectin Plus Albendazole | Ivermectin Plus Albendazole | Moxidectin +/- Albendazole (Pooled) | Ivermectin +/- Albendazole (Pooled) |
|---|---|---|---|---|---|---|
| Number of Participants with one or more Treatment Emergent Adverse Events (TEAEs) | 346 | 79 | 1199 | 288 | 1545 | 367 |
| Number of Participants with one or more TEAEs defined as a Mazzotti Reaction | 173 | 47 | 455 | 98 | 628 | 145 |
| Number of Participants with Severe (Gr 3 or 4) TEAE | 18 | 5 | 66 | 14 | 84 | 19 |
| Number of Participants with TEAE defined as Serious | 18 | 4 | 4 | 0 | 22 | 4 |
| Number of participants with TEAE leading to Death | 6 | 2 | 3 | 0 | 9 | 2 |
| Number of Participants with a TEAE considered Related to Moxidectin or Ivermectin | 189 | 50 | 576 | 128 | 765 | 178 |
| Number of Participants with a Severe TEAE considered Related to Moxidectin or Ivermectin | 0 | 0 | 0 | 0 | 0 | 0 |
| Number of Participants with a TEAE considered Related to Albendazole | 0 | 0 | 34 | 7 | 34 | 7 |
| Number of Participants with a Severe TEAE considered Related to Albendazole | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Adverse events were collected for all participants daily for 5 days and up to 3 months after treatment. More than 98% of participants completed a Month 3 visit.. Non-serious events are listed at a 0.1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moxidectin | 6/6,421 (0.1%) | 18/6,421 (0.3%) | 346/6,421 (5.4%) |
| Ivermectin | 2/1,605 (0.1%) | 4/1,605 (0.2%) | 79/1,605 (4.9%) |
| Moxidectin Plus Albendazole | 3/3,959 (0.1%) | 4/3,959 (0.1%) | 1,199/3,959 (30.3%) |
| Ivermectin Plus Albendazole | 0/994 (0%) | 0/994 (0%) | 288/994 (29%) |
| Moxidectin +/- Albendazole (Pooled) | 9/10,380 (0.1%) | 22/10,380 (0.2%) | 1,545/10,380 (14.9%) |
| Ivermectin +/- Albendazole (Pooled) | 2/2,599 (0.1%) | 4/2,599 (0.2%) | 367/2,599 (14.1%) |
| Event | Moxidectin | Ivermectin | Moxidectin Plus Albendazole | Ivermectin Plus Albendazole | Moxidectin +/- Albendazole (Pooled) | Ivermectin +/- Albendazole (Pooled) |
|---|---|---|---|---|---|---|
| EnteritisGastrointestinal disorders | 1/6421 | 1/1605 | 0/3959 | 0/994 | 1/10380 | 1/2599 |
| GastritisGastrointestinal disorders | 0/6421 | 1/1605 | 0/3959 | 0/994 | 0/10380 | 1/2599 |
| Hepatic cirrhosisHepatobiliary disorders | 0/6421 | 1/1605 | 0/3959 | 0/994 | 0/10380 | 1/2599 |
| Complicated malaria or malariaInfections and infestations | 4/6421 | 1/1605 | 0/3959 | 0/994 | 4/10380 | 1/2599 |
| ThrombophlebitisVascular disorders | 0/6421 | 1/1605 | 0/3959 | 0/994 | 0/10380 | 1/2599 |
| Cardiac FailureCardiac disorders | 2/6421 | 0/1605 | 0/3959 | 0/994 | 2/10380 | 0/2599 |
| PolydactylyCongenital, familial and genetic disorders | 0/6421 | 0/1605 | 1/3959 | 0/994 | 1/10380 | 0/2599 |
| Dental cariesGastrointestinal disorders | 0/6421 | 0/1605 | 1/3959 | 0/994 | 1/10380 | 0/2599 |
| PneumoniaInfections and infestations | 1/6421 | 0/1605 | 1/3959 | 0/994 | 2/10380 | 0/2599 |
| CellulitisInfections and infestations | 0/6421 | 0/1605 | 1/3959 | 0/994 | 1/10380 | 0/2599 |
| Event | Moxidectin | Ivermectin | Moxidectin Plus Albendazole | Ivermectin Plus Albendazole | Moxidectin +/- Albendazole (Pooled) | Ivermectin +/- Albendazole (Pooled) |
|---|---|---|---|---|---|---|
| Pruritis / rash pruritic/ rash/ urticariaSkin and subcutaneous tissue disorders | 92/6421 | 22/1605 | 360/3959 | 67/994 | 452/10380 | 89/2599 |
| Malaria / complicated malariaInfections and infestations | 50/6421 | 9/1605 | 232/3959 | 66/994 | 282/10380 | 75/2599 |
| HeadacheNervous system disorders | 84/6421 | 21/1605 | 161/3959 | 54/994 | 245/10380 | 75/2599 |
| Infections (various, not malaria)Infections and infestations | 24/6421 | 4/1605 | 89/3959 | 16/994 | 113/10380 | 20/2599 |
| Abdominal pain and/or distensionGastrointestinal disorders | 11/6421 | 0/1605 | 62/3959 | 20/994 | 73/10380 | 20/2599 |
| DiarrheaGastrointestinal disorders | 7/6421 | 2/1605 | 57/3959 | 16/994 | 64/10380 | 18/2599 |
| Myalgia / musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 9/6421 | 2/1605 | 39/3959 | 7/994 | 48/10380 | 9/2599 |
| Influenza-like illness, chills or pyrexiaGeneral disorders | 2/6421 | 0/1605 | 38/3959 | 8/994 | 40/10380 | 8/2599 |
| Cough / AsthmaRespiratory, thoracic and mediastinal disorders | 15/6421 | 3/1605 | 37/3959 | 8/994 | 52/10380 | 11/2599 |
| Peripheral swelling / swellingGeneral disorders | 0/6421 | 0/1605 | 33/3959 | 9/994 | 33/10380 | 9/2599 |
| Age, Categorical(Participants) | Moxidectin | Ivermectin | Moxidectin With Concomitant Albendazole | Ivermectin With Concomitant Albendazole | Total |
|---|---|---|---|---|---|
| <=18 years | 2015 | 461 | 1387 | 340 | 4203 |
| Between 18 and 65 years | 4069 | 1061 | 2409 | 610 | 8149 |
| >=65 years | 337 | 83 | 163 | 44 | 627 |
| Age, Continuous(years) | Moxidectin | Ivermectin | Moxidectin With Concomitant Albendazole | Ivermectin With Concomitant Albendazole | Total |
|---|---|---|---|---|---|
| Mean | 30.4 (4 to 93) | 31.2 (4 to 84) | 28.5 (4 to 91) | 28.6 (4 to 96) | 29.8 (4 to 96) |
| Sex: Female, Male(Participants) | Moxidectin | Ivermectin | Moxidectin With Concomitant Albendazole | Ivermectin With Concomitant Albendazole | Total |
|---|---|---|---|---|---|
| Female | 2954 | 724 | 1829 | 470 | 5977 |
| Male | 3467 | 881 | 2130 | 524 | 7002 |
| Race/Ethnicity, Customized(participants) | Moxidectin | Ivermectin | Moxidectin With Concomitant Albendazole | Ivermectin With Concomitant Albendazole | Total |
|---|---|---|---|---|---|
| Race - Black African | 6421 | 1605 | 3959 | 994 | 12979 |
| Region of Enrollment(participants) | Moxidectin | Ivermectin | Moxidectin With Concomitant Albendazole | Ivermectin With Concomitant Albendazole | Total |
|---|---|---|---|---|---|
| Congo, The Democratic Republic of the | 6421 | 1605 | 0 | 0 | 8026 |
| Côte D'Ivoire | 0 | 0 | 3959 | 994 | 4953 |
| Number of Participants with Onchocerca volvulus skin microfilariae (mf)(participants) | Moxidectin | Ivermectin | Moxidectin With Concomitant Albendazole | Ivermectin With Concomitant Albendazole | Total |
|---|---|---|---|---|---|
| Overall tested | 6271 | 1568 | 3282 | 826 | 11947 |
| Undetectable (skin mf =0) | 6065 | 1509 | 3067 | 751 | 11392 |
| Detectable (skin mf>0) | 206 | 59 | 215 | 75 | 555 |
| Number of participants with LF antigenemia and/or microfilaremia(participants) | Moxidectin | Ivermectin | Moxidectin With Concomitant Albendazole | Ivermectin With Concomitant Albendazole | Total |
|---|---|---|---|---|---|
| CFA Positive (Category 1-3) with or without microfilaremia | — | — | 107 | 23 | 130 |
| CFA negative | — | — | 3179 | 803 | 3982 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Deidentified individual participant data in the form of data listings and SDTM and ADaM datasets may be available for sharing on application to the Sponsor.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will become available 12 months after publication.
Access criteria: Provision of a methodologically sound and relevant proposal detailing the intended use of the data and relevant ethics approval for the proposed analysis, as applicable.
Data sharing details ↗ · www.medicinesdevelopment.com
Ran from May 2021 to primary completion in Sep 2024, 40 months.
Results were first posted in Feb 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Moxidectin · Albendazole
Medicines Development for Global Health